The NHLBI Grants NuvOx Pharma a 300K Grant to Study the Effects of Their Oxygen Therapeutic on Myocardial Infarction in a Pig Model

Tucson, AZ, April 14, 2017 –(– Evan Unger, MD, President and CEO of NuvOx Pharma, announced that NuvOx Pharma has been awarded a grant from the National Heart, Lung, and Blood Institute (NHLBI) entitled “Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management,” for a total of $317,743. This grant will be used to support research to study NVX-308 as a cardioprotectant to reduce damage to the heart following myocardial infarction.

Read full article here